Document is current
Any future updates will be listed below
-
Authors
Piechotta, Vanessa
Mellinghoff, Sibylle C. https://orcid.org/0000-0003-3928-2503
Hirsch, Caroline https://orcid.org/0000-0002-2011-1010
Brinkmann, Alice
Iannizzi, Claire
Kreuzberger, Nina https://orcid.org/0000-0001-8922-0488
Adams, Anne https://orcid.org/0000-0003-3286-1131
Monsef, Ina
Stemler, Jannik
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
Bröckelmann, Paul J. https://orcid.org/0000-0001-9662-9900
Skoetz, Nicole https://orcid.org/0000-0003-4744-6192
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KG2104, 01KG2104, 01KG2104, 01KG2104, 01KG2104, 01KG2104, 01KG2104)
Deutsche Krebshilfe (70113307)
- License Information
-
More Information
Article History
Received: 31 March 2022
Revised: 10 May 2022
Accepted: 19 May 2022
First Online: 31 May 2022
Competing interests
: VP, AB, CH, CI, AA, IM, NK, JS, PJB, and NS declare no financial conflicts of interest with regard to the present study. SCM reports grants from DZIF. OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.
